Agilent v Synthego (Fed. Cir., June 11, 2025) 2023-2186
This Federal Circuit opinion concerns an appeal from Agilent Technologies, Inc. against Synthego Corp., concerning the patentability of gene-editing technology related to CRISPR-Cas systems. Agilent appealed decisions by the Patent Trial and Appeal Board, which found all claims of Agilent's U.S. Patent Nos. 10,337,001 and 10,900,034 unpatentable due to anticipation or obviousness based on prior art. The core of the dispute revolves around whether earlier works, particularly "Pioneer Hi-Bred," "Threlfall," and "Deleavey," expressly disclosed or enabled the chemically modified guide RNAs…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.